SCHEMBL4384590

SCHEMBL4384590

COP1(=O)OBO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL459640 0.69
SCHEMBL13733286 0.62
SCHEMBL16272675 0.61 MEN1 (0.32)
SCHEMBL9122573 0.61 ACHE (0.44)
SCHEMBL2633114 0.61
SCHEMBL19414249 0.59
SCHEMBL13607127 0.59
SCHEMBL2633117 0.59
SCHEMBL17316723 0.59
SCHEMBL17248102 0.56

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023152371-A1 GUIDE OLIGONUCLEOTIDES FOR NUCLEIC ACID EDITING IN THE TREATMENT OF HYPERCHOLESTEROLEMIA PROQR THERAPEUTICS II B.V. (NL) 2023-08-17 WO claimed
US-20230039928-A1 Antisense oligonucleotides for nucleotide deamination in the treatment of Stargardt disease PROQR THERAPEUTICS II B.V. (NL) 2023-02-09 US claimed
WO-2021130313-A1 ANTISENSE OLIGONUCLEOTIDES FOR NUCLEOTIDE DEAMINATION IN THE TREATMENT OF STARGARDT DISEASE PROQR THERAPEUTICS II B.V. (NL) 2021-07-01 WO claimed
EP-4400169-A2 RNA MODULATING OLIGONUCLEOTIDES WITH IMPROVED CHARACTERISTICS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS Vico Therapeutics B.V. (NL) 2024-07-17 EP disclosed
WO-2024127026-A1 MEMBRANE FILTRATION-ASSISTED SOLUTION PHASE OLIGONUCLEOTIDE SYNTHESIS Exactmer Limited (GB) 2024-06-20 WO disclosed
EP-3604536-B1 RNA MODULATING OLIGONUCLEOTIDES WITH IMPROVED CHARACTERISTICS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS VICO THERAPEUTICS B V (NL) 2024-05-29 EP disclosed
CN-118103384-A Solution phase polymer synthesis 艾克特姆有限公司 2024-05-28 CN disclosed
EP-4370677-A1 OLIGONUCLEOTIDE FOR INHIBITING QUAKING ACTIVITY Academisch Ziekenhuis Leiden h.o.d.n. LUMC (NL) 2024-05-22 EP disclosed
US-20240141340-A1 ANTISENSE OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF CORNEAL DYSTROPHIES PROQR THERAPEUTICS II B.V. (NL) 2024-05-02 US disclosed
WO-2024074663-A1 ULTRAFILTRATION METHODS BioSpring Gesellschaft für Biotechnologie mbH (DE) 2024-04-11 WO disclosed
EP-4349459-A1 ULTRAFILTRATION METHODS USING OSMOLYTES ON THE PERMEATE SIDE BioSpring Gesellschaft für Biotechnologie mbH (DE) 2024-04-10 EP disclosed
US-6180766-B1 OLIGONUCLEOTIDE WITH UNCHARGED INTERNUCLEOTIDE LINKAGE(S) OF 3',5'-O,O-((CARBORAN-1-YL-METHYL)PHOSPHONATE); MADE BY REACTING O-METHYL(O-CARBORAN-1-YL)METHYL PHOSPHONATE WITH PROTECTED NUCLEOSIDE; USE IN BORON NEUTRON CAPTURE THERAPY DEPARTMENT OF VETERANS AFFAIRS 2001-01-30 US disclosed
US-5872107-A ANTICARCINOGENIC AGENTS CAPTURE THERAPY FOR TUMORS EMORY UNIVERSITY (US) 1999-02-16 US disclosed
EP-0788364-A4 TREATMENT OF UROGENITAL CANCER WITH BORON NEUTRON CAPTURE THERAPY UNIV EMORY (US) 1998-05-06 EP disclosed
EP-0788364-A1 TREATMENT OF UROGENITAL CANCER WITH BORON NEUTRON CAPTURE THERAPY EMORY UNIVERSITY (US) 1997-08-13 EP disclosed
EP-0731808-A4 NUCLEOSIDES AND OLIGONUCLEOTIDES CONTAINING BORON CLUSTERS UNIV EMORY (US) 1997-04-02 EP disclosed
US-5599796-A USING BORON CLUSTER-CONTAINING NUCLEOSIDES OR OLIGONUCLEOTIDES; PARTICULARLY EFFECTIVE FOR BLADDER, PROSTATE AND KIDNEY EMORY UNIVERSITY (US) 1997-02-04 US disclosed
EP-0731808-A1 NUCLEOSIDES AND OLIGONUCLEOTIDES CONTAINING BORON CLUSTERS EMORY UNIVERSITY (US) 1996-09-18 EP disclosed
WO-1996014073-A1 TREATMENT OF UROGENITAL CANCER WITH BORON NEUTRON CAPTURE THERAPY EMORY UNIVERSITY (US) 1996-05-17 WO disclosed
WO-1995015333-A1 NUCLEOSIDES AND OLIGONUCLEOTIDES CONTAINING BORON CLUSTERS EMORY UNIVERSITY (US) 1995-06-08 WO disclosed